Decoy Therapeutics Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Decoy Therapeutics Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 33,870% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 97% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Decoy Therapeutics Inc. owes $0.52 for every $1 it owns. Decoy Therapeutics Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
0.1Investors pay $0.1 for every $1 of Decoy Therapeutics Inc.'s yearly profit, lower than 97% of Healthcare companies in United States.
P/B ratio
0.57The share price is 0.57 times Decoy Therapeutics Inc.'s book value per share, lower than 89% of Healthcare companies in United States.
Market cap
$2 MThe total market value of all of Decoy Therapeutics Inc.'s shares at today's price (share price × number of shares), smaller than 97% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$4 MWhat Decoy Therapeutics Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.81Net worth divided by the number of shares. The share price of $1.03 is 0.6 times this, which is the P/B above.
Return on equity (ROE)
-827.8%Decoy Therapeutics Inc. lost 827.8% of its shareholders' money over the last year, lower than 96% of Healthcare companies in United States.
Owes vs Owns
0.52×Decoy Therapeutics Inc. owes $0.52 for every $1 it owns (moderate), higher than 58% of Healthcare companies in United States.
Dividend yield
NoneDecoy Therapeutics Inc. does not currently pay a dividend.
Profit growth
LossDecoy Therapeutics Inc. made a loss in each of the last two years.
Questions
What is Decoy Therapeutics Inc.'s P/E ratio?
Investors pay $0.1 for every $1 of Decoy Therapeutics Inc.'s yearly profit, lower than 97% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Decoy Therapeutics Inc.: $2 M ÷ $4 M (30 Jun 2026) = 0.6.
What is Decoy Therapeutics Inc.'s return on equity?
Decoy Therapeutics Inc. lost 827.8% of its shareholders' money over the last year, lower than 96% of Healthcare companies in United States.
How much does Decoy Therapeutics Inc. owe compared with what it owns?
Decoy Therapeutics Inc. owes $0.52 for every $1 it owns (moderate), higher than 58% of Healthcare companies in United States.
Does Decoy Therapeutics Inc. pay a dividend?
No. Decoy Therapeutics Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.